{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:47:47Z","timestamp":1782910067018,"version":"3.54.5"},"reference-count":27,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Oral prednisolone (PSL) and budesonide multi-matrix (BUD-MMX) are used to induce remission in ulcerative colitis (UC); however, their therapeutic positioning remains unclear. Comparative data from real-world practices are limited. This study assessed the efficacy and safety of PSL and BUD-MMX in patients with active UC. Methods: Consecutive outpatients with UC initiated on oral PSL or BUD-MMX at two tertiary referral centers were included. The primary outcome was clinical remission at week 8, defined as a partial Mayo score (PMS) \u2264 1 with a rectal bleeding subscore of 0. Secondary outcomes included clinical response and safety. Pre-specified subgroup analyses were performed according to baseline disease activity. Results: Sixty PSL-treated and 40 BUD-MMX-treated patients were evaluated at week 8. Clinical remission was achieved in 65.0% and 55.0% of the PSL and BUD-MMX groups, respectively, whereas a clinical response was observed in 75.0% and 62.5%, respectively. No patient with a baseline PMS of 2\u20133 was initiated on PSL. Among patients with a baseline PMS of 4\u20135, the remission and response rates at week 8 were similar between the groups. In contrast, remission in patients with a baseline PMS \u2265 6 was numerically lower in the BUD-MMX group. Treatment escalation rates were comparable in the overall cohort, whereas adverse events were more frequent in the PSL group (23.3% vs. 2.4%). Conclusions: Treatment selection between PSL and BUD-MMX appeared to reflect baseline disease activity, with a partial overlap in the moderate clinical range. BUD-MMX may be a reasonable initial option for selected patients.<\/jats:p>","DOI":"10.3390\/jcm15135115","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:41:01Z","timestamp":1782902461000},"page":"5115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Oral Prednisolone and Budesonide MMX for Outpatient Induction Therapy in Active Ulcerative Colitis: A Multicenter Retrospective Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-2426","authenticated-orcid":false,"given":"Kentaro","family":"Kojima","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-3956","authenticated-orcid":false,"given":"Jun","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, 4-6-1 Noishiki, Gifu 500-8717, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichi","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3127-8054","authenticated-orcid":false,"given":"Naoya","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4995-0875","authenticated-orcid":false,"given":"Hiroki","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, 4-6-1 Noishiki, Gifu 500-8717, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, 4-6-1 Noishiki, Gifu 500-8717, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-1019","authenticated-orcid":false,"given":"Sachiyo","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ibuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Gifu Prefectural General Medical Center, 4-6-1 Noishiki, Gifu 500-8717, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Berre","year":"2023","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG Clinical Guideline Update: Ulcerative Colitis in Adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am. J. Gastro-Enterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in ulcerative colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00002018-200730100-00005","article-title":"Corticosteroid-induced adverse events in adults: Frequency, screening and prevention","volume":"30","author":"Fardet","year":"2007","journal-title":"Drug Saf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.cgh.2025.05.019","article-title":"Appropriate Use and Complications of Corticosteroids in Inflammatory Bowel Disease: A Comprehensive Review","volume":"23","author":"Feuerstein","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2125.2005.02517.x","article-title":"Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation","volume":"61","author":"Brunner","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/TCRM.S263835","article-title":"Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety","volume":"17","author":"Maconi","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide MMX\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE I study","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: Results from the randomised CORE II study","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ecco-jcc\/jjv101","article-title":"Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: A Pooled Safety Analysis","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rosiou, K., San, E.O.M., Kumar, A., Esquivel, K., Almas, S., Stokes, D., Ng, T., Jayasooriya, N., Ranasinghe, I., and Pollok, R. (2021). Comparative outcomes of budesonide MMX versus prednisolone for ulcerative colitis: Results from a British retrospective multi-centre real-world study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194329"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s43162-025-00519-5","article-title":"Budesonide MMX versus prednisolone in mesalamine-refractory mild to moderate ul-cerative colitis: A randomized controlled clinical trial","volume":"37","author":"Osman","year":"2025","journal-title":"Egypt. J. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/apt.17961","article-title":"Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retro-spective study in Japan","volume":"59","author":"Akiyama","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/ecco-jcc\/jjx032","article-title":"Budesonide multimatrix Is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: A randomised, placebo-controlled Trial","volume":"11","author":"Rubin","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/2050640619864848","article-title":"A multicentre prospective cohort study assessing the effectiveness of budesonide MMX\u00ae (Cortiment\u00aeMMX\u00ae) for active, mild-to-moderate ulcerative colitis","volume":"7","author":"Danese","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/2050640619864257","article-title":"Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience","volume":"7","author":"Maconi","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/apt.13076","article-title":"Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: Pooled analysis of two phase 3 studies","volume":"41","author":"Sandborn","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","first-page":"154","article-title":"Assessment of the effectiveness of Budesonide MMX\u00ae for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study","volume":"18","author":"Jesionowski","year":"2023","journal-title":"Prz. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000501004","article-title":"Predictors of inadequate response to budesonide multimatrix in real-world patients with ulcerative colitis","volume":"4","author":"Greenberg","year":"2019","journal-title":"Inflamm. Intest Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bcp.13456","article-title":"Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis","volume":"84","author":"Bonovas","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/17474124.2019.1604219","article-title":"A current overview of corticosteroid use in active ulcerative colitis","volume":"13","author":"Salice","year":"2019","journal-title":"Expert Rev. Gas.-Troenterol Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.3748\/wjg.v23.i35.6385","article-title":"Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?","volume":"23","author":"Vasudevan","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/apt.13803","article-title":"Systematic review: Second-generation vs. conventional corticosteroids for induction of remission in ulcerative coli-tis","volume":"44","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"i2081","DOI":"10.1093\/ecco-jcc\/jjae190.1313","article-title":"P1139 A real-world, observational study comparing the side effects of budesonide MMX with prednisolone and the resolution of symptoms in patients with mild to moderate ulcerative colitis","volume":"19","author":"Walsh","year":"2025","journal-title":"J. Crohns Colitis"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:03:39Z","timestamp":1782907419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":27,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135115"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135115","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}